JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Stock List・Adaptive Biotechnologies Corp

Search

Adaptive Biotechnologies Corp

Closed

13.67 -5.59

Overview

Share price change

24h

Current

Min

13.61

Max

14.74

Key metrics
By Trading Economics
Income	-23M -14M
Sales	-22M 72M
Profit margin	-18.944
Employees	624
EBITDA	-23M -6.4M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+45.97% upside

Dividends
By Dow Jones
Next Earnings	5 May 2026

Market Stats
By TradingEconomics
Market Cap	-537M 2.3B
Previous open	19.26
Previous close	13.67

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

8.81 / 10.18 Support & Resistance

Adaptive Biotechnologies Corp Chart

Past performance is not a reliable indicator of future results.

Related News

4 May 2026, 22:17 UTC

Earnings

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 May 2026, 23:47 UTC

Earnings

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 May 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 May 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 May 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 May 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 May 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 May 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 May 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 May 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 May 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 May 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Shareholders to Own About 51% of Combined Company

4 May 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Board Unanimously Endorsed, Supported Deal

4 May 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Deal Unanimously Recommended by Vault Board

4 May 2026, 22:39 UTC

Acquisitions, Mergers, Takeovers

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 May 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources to Acquire All Ordinary Shares in Vault

4 May 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources, Vault Minerals Agree to Merger of Equals

4 May 2026, 22:37 UTC

Earnings

Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 May 2026, 22:26 UTC

Earnings

Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 May 2026, 22:02 UTC

Earnings

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 May 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 May 2026, 21:52 UTC

Earnings

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 May 2026, 21:50 UTC

Earnings

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 May 2026, 21:50 UTC

Earnings

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 May 2026, 21:49 UTC

Earnings

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 May 2026, 21:44 UTC

Earnings

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 May 2026, 21:44 UTC

Earnings

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 May 2026, 21:43 UTC

Earnings

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 May 2026, 21:41 UTC

Earnings

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 May 2026, 21:40 UTC

Earnings

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Peer Comparison

Price change

Adaptive Biotechnologies Corp Forecast

Price Target

By TipRanks

45.97% upside

12 Months Forecast

Average 20.83 USD 45.97%

High 22 USD

Low 20 USD

Based on 7 Wall Street analysts offering 12 month price targets forAdaptive Biotechnologies Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

6

Buy

1

Hold

0

Sell

Based on 7 analysts giving stock ratings to Adaptive Biotechnologies Corp - Dist in the past 3 months.

Technical Score

By Trading Central

8.81 / 10.18Support & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Other stocks from the sector

JNJ

Johnson and Johnson

225.57

UNH

UnitedHealth Group Inc

363.82

TMO

Thermo Fisher Scientific Inc

466.62

ISRG

Intuitive Surgical Inc

451.55

ABT

Abbott Laboratories

87.15

Live chat